Building a Broad Pipeline

Gylden is advancing a growing pipeline of therapeutic programs powered by two proprietary intradermal platforms. From our Phase 3 migraine program to next-generation vaccines and immunotherapies, each program is built on the unique biology of the dermis and the potential of precision intradermal delivery.

Interested in partnering with Gylden?

Our proprietary delivery and immune activation platforms are designed to support a broad range of therapeutic applications. We welcome discussions with pharmaceutical, biotechnology, and strategic partners exploring next-generation intradermal therapies.